William Blair initiated coverage on AAPG with an Outperform rating and a $31 target, highlighting three pivotal 2027 readouts for HQP1351 and lisaftoclax. Positive results and Takeda royalties could unlock multi-billion-dollar opportunities in CML and MDS/CLL/SLL, supporting a potential re-rating as enrollment concludes by 2026-27 and data readouts arrive in 2027 with possible 2028 approvals.
JPMorgan initiated coverage on AAPG with an Overweight rating. Olverembatinib and lisaftoclax drive AAPG's valuation as late-stage assets. AAPG's 2024 sales projected at $134.3 million, up 342% year-over-year. JP Morgan estimates peak sales for olverembatinib at 1.6 billion Yuan by 2030. AAPG stock rose 11.6% to $20.50 following the report.
